Incentives

NHS England antibiotic procurement pilot project: Update webinar on 25 Mar 2020

Dear All, This email was just today received from the team leading the NHS England antibiotic procurement project (go here for a prior newsletter describing the project): Dear Stakeholders, In November 2019, we held a stakeholder webinar to share our response to the comments raised in targeted engagement  and to outline proposals for the procurement process.

Read More »

New economic models for antibiotics: Are we there yet? No, but we ARE on the road

Dear All, The Duke-Margolis team hosted an excellent full-day workshop on 16 Jan 2020. Entitled “Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives” and chaired by Mark McClellan, the workshop’s outstanding cast of presenters and discussants provided a thorough discussion of both the need for new payment models and and the many ongoing activities focused

Read More »

CC4CARB solicitation is out (16 Mar 2020 deadline) / Superb WSJ podcast on antibiotic economics

Dear All, I wrote on 3 Jan 2020 (link) about the NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The formal solicitation has now gone live and can be found here. The deadline for applications is 16 Mar 2020. Get to it! In parallel, there is a superb Wall Street Journal podcast dated 13 Jan 2020 about

Read More »

Japan’s antibacterial R&D landscape / Japan calls for Pull incentives

Dear All: Late last year, I had the opportunity to hear a presentation on antibiotic R&D in Japan by Norio Ohmagari. Based in Tokyo at the National Center for Global Health and Medicine Hospital (link), Norio is Director of its (i) AMR Clinical Reference Center, (ii) Disease Control and Prevention Center, and (iii)  WHO Collaborating

Read More »

Extended deadline: NIAID call for proposals for therapeutics & vaccines for resistant bacteria

Also note several new webinars in the forward meeting list! Dear All: NIAID currently has an open BAA (Broad Agency Announcement, HHS-NIH-NIAID-BAA2019-1, link), that calls for proposals across three research areas: Medical Countermeasures (MCMs), therapeutics for resistant bacteria, and vaccines for resistant bacteria. The deadline for Research Area 001 (MCMs) is still 20 May 2019, but the

Read More »

Go, BARDA! / Outstanding Op-Ed in Forbes by Rick Bright

Dear All: Rick Bright, Director of BARDA, posted an outstanding commentary (link) in Forbes on 10 May 2019 on the Achaogen story (for more background, see my prior Scary/Scarier/Scariest blogs #1 and #2). Here are three excerpts from his commentary: “Since 2010, the Biomedical Advanced Research and Development Authority (BARDA) has been a leader in the fight against

Read More »

Start your engines! BARDA antibiotic procurement RFP / CARB-X 2019 funding round webinar

Dear All: Two things of note this afternoon… First, the previously noted BARDA RFP to acquire biothreat antibiotics is now posted here with submissions accepted through 21 June 2019: “Under this RFP, BARDA plans to support the procurement of antibiotic(s), which will either be delivered to the ASPR/SNS or maintained as VMI, using Project BioShield (PBS) funds. “PBS funds will also support

Read More »
Scroll to Top